CD44 and neoplasm: In view of the discrepant malignant properties of 143-B shCD44 cells in vitro and in vivo, we assessed the expression of immunoreactive CD44 by immunohistochemistry with Hermes3 antibodies in primary tumor tissue and lung metastases derived from 143-B shCD44 cells and compared it with 143-B EV and 143-B Ctrl shRNA cell-derived tumors.